inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: 1. individuals \>/= 18 years of age at the time of consent. 2. received and completed primary mrna covid-19 vaccine under eua dosing guidelines and one or two doses of ad26.cov2.s at least 12 weeks prior to enrollment (cohort 1 only). 3. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. 4. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.\* \* note: healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. 5. female participants of childbearing potential may be enrolled in the study, if all of the following apply: * practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), * has agreed to continue adequate contraception through 3 months following the booster dose, * has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), * is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: 1. individuals \>/= 18 years of age at the time of consent. 2. received and completed primary mrna covid-19 vaccine under eua dosing guidelines and one or two doses of ad26.cov2.s at least 12 weeks prior to enrollment (cohort 1 only). 3. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. 4. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.\* \* note: healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. 5. female participants of childbearing potential may be enrolled in the study, if all of the following apply: * practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), * has agreed to continue adequate contraception through 3 months following the booster dose, * has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), * is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: individuals >/= 18 years of age at the time of consent. received and completed primary mrna covid-19 vaccine under eua dosing guidelines and one or two doses of ad26.cov2.s at least 12 weeks prior to enrollment (cohort 1 only). willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. female participants of childbearing potential may be enrolled in the study, if all of the following apply: practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), has agreed to continue adequate contraception through 3 months following the booster dose, has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: individuals >/= 18 years of age at the time of consent. received and completed primary mrna covid-19 vaccine under eua dosing guidelines and one or two doses of ad26.cov2.s at least 12 weeks prior to enrollment (cohort 1 only). willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. female participants of childbearing potential may be enrolled in the study, if all of the following apply: practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), has agreed to continue adequate contraception through 3 months following the booster dose, has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: individuals >/= 18 years of age at the time of consent. received and completed primary mrna covid-19 vaccine under eua dosing guidelines or two doses of ad26.cov2.s at least 12 weeks prior to enrollment (cohort 1 only). willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. female participants of childbearing potential may be enrolled in the study, if all of the following apply: practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), has agreed to continue adequate contraception through 3 months following the booster dose, has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: individuals >/= 18 years of age at the time of consent. received and completed primary mrna covid-19 vaccine under eua dosing guidelines or two doses of ad26.cov2.s at least 12 weeks prior to enrollment (cohort 1 only). willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. female participants of childbearing potential may be enrolled in the study, if all of the following apply: practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), has agreed to continue adequate contraception through 3 months following the booster dose, has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: individuals >/= 18 years of age at the time of consent. received and completed coronavirus disease 2019 vaccine under emergency use authorization (eua) dosing guidelines at least 12 weeks prior to enrollment (cohort 1 only). willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. female participants of childbearing potential may be enrolled in the study, if all of the following apply: practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), has agreed to continue adequate contraception through 3 months following the booster dose, has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: individuals >/= 18 years of age at the time of consent. received and completed coronavirus disease 2019 vaccine under emergency use authorization (eua) dosing guidelines at least 12 weeks prior to enrollment (cohort 1 only). willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. female participants of childbearing potential may be enrolled in the study, if all of the following apply: practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), has agreed to continue adequate contraception through 3 months following the booster dose, has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: 1. individuals >/= 18 years of age at the time of consent. 2. received and completed coronavirus disease 2019 vaccine under emergency use authorization (eua) dosing guidelines at least 12 weeks prior to enrollment (cohort 1 only). 3. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. 4. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. 5. female participants of childbearing potential may be enrolled in the study, if all of the following apply: - practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), - has agreed to continue adequate contraception through 3 months following the booster dose, - has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), - is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: 1. individuals >/= 18 years of age at the time of consent. 2. received and completed coronavirus disease 2019 vaccine under emergency use authorization (eua) dosing guidelines at least 12 weeks prior to enrollment (cohort 1 only). 3. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. 4. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. 5. female participants of childbearing potential may be enrolled in the study, if all of the following apply: - practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), - has agreed to continue adequate contraception through 3 months following the booster dose, - has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), - is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: individuals >/= 18 years of age at the time of consent. received and completed coronavirus disease 2019 vaccine under emergency use authorization (eua) dosing guidelines at least 12 weeks prior to enrollment (cohort 1 only). willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. female participants of childbearing potential may be enrolled in the study, if all of the following apply: practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), has agreed to continue adequate contraception through 3 months following the booster dose, has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: individuals >/= 18 years of age at the time of consent. received and completed coronavirus disease 2019 vaccine under emergency use authorization (eua) dosing guidelines at least 12 weeks prior to enrollment (cohort 1 only). willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health.* * note: heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. female participants of childbearing potential may be enrolled in the study, if all of the following apply: practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), has agreed to continue adequate contraception through 3 months following the booster dose, has a negative pregnancy test at screening and on the day of the first study vaccine dose (day 1), is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: 1. individuals >/= 18 years of age at the time of consent. 2. received and completed coronavirus disease 2019 vaccine under emergency use authorization (eua) dosing guidelines at least 12 weeks and no more than 20 weeks prior to enrollment (cohort 1 only). 3. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. 4. determined by medical history, targeted physician examination and clinical judgement of the investigator to be in good health.* * note: heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. 5. female participants of childbearing potential may be enrolled in the study, if all of the following apply: - practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), - has agreed to continue adequate contraception through 3 months following the booster dose, - has a negative pregnancy test at screening and on the day of the first vaccine dose (day 1), - is not currently breastfeeding.

inclusion criteria: participants must meet all of the following criteria to be eligible to participate in this study: 1. individuals >/= 18 years of age at the time of consent. 2. received and completed coronavirus disease 2019 vaccine under emergency use authorization (eua) dosing guidelines at least 12 weeks and no more than 20 weeks prior to enrollment (cohort 1 only). 3. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures. 4. determined by medical history, targeted physician examination and clinical judgement of the investigator to be in good health.* * note: heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. 5. female participants of childbearing potential may be enrolled in the study, if all of the following apply: - practiced adequate contraception for 28 days prior to the first dose of vaccine (day 1), - has agreed to continue adequate contraception through 3 months following the booster dose, - has a negative pregnancy test at screening and on the day of the first vaccine dose (day 1), - is not currently breastfeeding.